Severity: Warning
Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09&a=1): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Filename: helpers/my_audit_helper.php
Line Number: 197
Backtrace:
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 197
Function: file_get_contents
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 271
Function: simplexml_load_file_from_url
File: /var/www/html/application/helpers/my_audit_helper.php
Line: 3145
Function: getPubMedXML
File: /var/www/html/application/controllers/Detail.php
Line: 575
Function: pubMedSearch_Global
File: /var/www/html/application/controllers/Detail.php
Line: 489
Function: pubMedGetRelatedKeyword
File: /var/www/html/index.php
Line: 316
Function: require_once
Gastroparesis is a chronic gastrointestinal disorder characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms such as nausea, vomiting, and abdominal pain. Despite its significant impact on patient quality of life, effective management remains challenging. Current treatments, such as prokinetic agents and antiemetics, offer symptomatic relief but have limitations, necessitating the exploration of new approaches. We reviewed the most recent literature using PubMed and Medline, focusing on studies that address the etiology, pathophysiology, and management of gastroparesis, including novel pharmacological agents, endoscopic techniques, and lifestyle modifications. Emerging therapies, including gastric peroral endoscopic myotomy and ghrelin agonists, show promise in improving patient outcomes. In this review, we examine these therapeutic advancements and discuss their potential role in the future management of gastroparesis.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.23736/S2724-5985.24.03804-X | DOI Listing |
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!